-

UPDATED TIME: Alexion Fourth Quarter and Full Year 2019 Results Conference Call at 7:30am ET on Thursday, January 30, 2020

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has updated the time of its fourth quarter and full year 2019 earnings call on January 30, 2020 to 7:30 a.m. Eastern Time. The call had previously been scheduled for 8:00 a.m. ET. All other aspects of the call remain unchanged.

The Company will report its financial results for the fourth quarter and full year ended December 31, 2019 before the US financial markets open on January 30, 2020.

To participate in the conference call, dial (866) 762-3111 (USA) or (210) 874-7712 (International), conference ID 3571658 shortly before 7:30 a.m. ET. The audio webcast can be accessed on the Investor page of http://ir.alexion.com and an archived version will be available for a limited time following the presentation.

[ALXN-G]

Contacts

Investors
Susan Altschuller, Ph.D.
Vice President, Investor Relations
(857) 338-8788

Industry:

Alexion Pharmaceuticals, Inc.

NASDAQ:ALXN
Release Versions
English

Contacts

Investors
Susan Altschuller, Ph.D.
Vice President, Investor Relations
(857) 338-8788

More News From Alexion Pharmaceuticals, Inc.

Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

BOSTON--(BUSINESS WIRE)--Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)....

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the EHA Congress 2021...

 Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

BOSTON--(BUSINESS WIRE)--Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)...
Back to Newsroom